In pursuing more effective therapies for obesity and diabetes (Rodriguez et al., 2023), CCK analog NN9056 has emerged as a promising candidate, especially when combined with the GLP-1R agonist semaglutide (Zhou et al., 2024). Here, GLP1R is linked to obesity disorder.